SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Paxlovid

ENTA·ENANTA PHARMACEUTICALS INC
BEARISH
Drug Impact Rating3/10
Trial phase
Approved (Pfizer)
Time to market
Paxlovid is already approved and marketed by Pfizer. Enanta has no timeline to market for any of its own pipeline drugs; zelicapavir's registrational Phase 2b/3 data is expected in 2027, with potential FDA submission following positive results.
Why 3/10
Paxlovid is an already-approved, marketed drug owned by Pfizer (PFE), not Enanta. Enanta's connection was through patent litigation that has now fully concluded against Enanta (US Federal Circuit invalidated the '953 patent June 2026, en banc denied September 2026; UPC invalidated European patent October 29, 2026). There is no upcoming binary catalyst for Enanta related to Paxlovid. Enanta's next hard catalyst is Q4 2026 earnings on November 16, 2026, which is an earnings report, not a drug catalyst. ImpactScore is 3 because Paxlovid is an approved drug with no pending regulatory decision for Enanta, and the litigation that connected Enanta to Paxlovid has fully resolved.
Actionable Insight BEARISH

Paxlovid is Pfizer's drug, not Enanta's. Enanta's patent litigation against Pfizer over Paxlovid has now been fully resolved against Enanta on both sides of the Atlantic: the US Federal Circuit invalidated the '953 patent in June 2026 (en banc denied September 2026), and the UPC invalidated the European EP 265 patent on October 29, 2026. With no further appeal options disclosed, the litigation catalyst is dead. Enanta's stock now trades entirely on its RSV pipeline (zelicapavir Phase 2b/3 RESOLVE trial, topline 2027; EDP-323 Phase 2a) and its AbbVie royalty revenue stream. The next hard catalyst is Q4 2026 earnings on November 16, 2026.

Price Chart

Loading chart...

Executive Summary

Paxlovid is Pfizer's (PFE) FDA-approved oral antiviral for COVID-19, not a drug owned or developed by Enanta Pharmaceuticals (ENTA). Enanta's connection to Paxlovid was purely through patent litigation: it sued Pfizer alleging Paxlovid infringed its patents. That litigation has now fully failed. The US Federal Circuit invalidated Enanta's '953 patent in June 2026 and denied en banc rehearing in September 2026. The European Unified Patent Court invalidated Enanta's EP 265 patent on October 29, 2026 (yesterday), ending the EU case. Enanta is a clinical-stage biotech with no approved products; its revenue comes from AbbVie HCV drug royalties. Its pipeline focuses on RSV antivirals (zelicapavir in a registrational Phase 2b/3 trial that began dosing October 26, 2026; EDP-323 in Phase 2a). With the Paxlovid patent litigation fully resolved against Enanta, the stock's thesis now rests entirely on its RSV pipeline and AbbVie royalty stream.

How It Works

Paxlovid is a combination of two antiviral pills: nirmatrelvir (which blocks a key enzyme the SARS-CoV-2 virus needs to replicate) and ritonavir (which boosts nirmatrelvir levels in the body by slowing its breakdown). It is taken orally for five days to treat mild-to-moderate COVID-19 in high-risk adults.

Trial Status

Paxlovid is fully approved by the FDA (NDA 217188) for treatment of mild-to-moderate COVID-19 in high-risk adults. It was initially authorized under EUA in December 2021 and received full FDA approval in May 2023. Enanta's own pipeline: zelicapavir (RSV N-protein inhibitor) is in a registrational Phase 2b/3 trial (RESOLVE) that began dosing October 26, 2026, with topline Phase 2b data expected in 2027; EDP-323 (RSV L-protein inhibitor) completed a positive Phase 2a human challenge study in 2024-2025; EDP-978 is in Phase 1.

The Two-Sided Case

▲ Bull Case5
Enanta has $211.5M in cash (June 30, 2026) with runway into 2029, providing financial stability to advance its RSV pipeline without near-term dilution.
Zelicapavir (RSV N-protein inhibitor) showed positive Phase 2b data in high-risk adults (Sept 2025) and has Fast Track designation from the FDA; the registrational RESOLVE trial began dosing October 26, 2026.
EDP-323 (RSV L-protein inhibitor) demonstrated 'unprecedented antiviral activity' in a Phase 2a human challenge study, with statistically significant viral load and symptom reductions.
Analyst consensus is strongly bullish: 11 of 12 analysts rate Buy or Strong Buy, with a mean price target of $21.83 (89% upside from $11.55).
The patent litigation overhang is now fully removed, allowing investors to focus on the RSV pipeline thesis.
▼ Bear Case5
Enanta's US and European Paxlovid-related patents have both been ruled invalid (Federal Circuit June 2026, UPC October 2026), eliminating any potential royalty or damages stream from Pfizer's Paxlovid sales.
Enanta has no approved products of its own; its only revenue ($14.36M in Q3 2026) comes from AbbVie HCV royalty payments that are declining.
The RSV pipeline is still early-stage: zelicapavir's registrational Phase 2b/3 trial (RESOLVE) only began dosing in late October 2026, with topline data not expected until 2027, leaving a long binary-free period.
CEO Jay R. Luly is retiring by February 2027, creating leadership transition risk during a critical pipeline execution phase.
The stock trades near its 52-week low of $10.22, reflecting the market's disappointment with the patent losses.

Upcoming Catalysts

  • Q4 2026 earnings report on November 16, 2026 (after market close)
  • Zelicapavir Phase 2b topline data from RESOLVE trial expected in 2027
  • Zelicapavir pediatric Phase 2b data expected in 2027
  • CEO succession announcement (Jay Luly retiring by February 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ENANTA PHARMACEUTICALS INC 8-K ENTA ·Originating report

Sources · 11

Hover a chip for the title
1 pfizer.com2 ir.enanta.com3 law.justia.com4 law.justia.com5 sec.gov6 ir.enanta.com7 ir.enanta.com8 biospace.com9 fiercebiotech.com10 legalnewsfeed.com11 stocktitan.net